These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 33106437

  • 21. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
    Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F, RALPEP Study Group.
    J Antimicrob Chemother; 2016 Jul; 71(7):1987-93. PubMed ID: 26994089
    [Abstract] [Full Text] [Related]

  • 22. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
    McAllister JW, Towns JM, Mcnulty A, Pierce AB, Foster R, Richardson R, Carr A.
    AIDS; 2017 Jun 01; 31(9):1291-1295. PubMed ID: 28301425
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
    Maggiolo F, Rizzardini G, Raffi F, Pulido F, Mateo-Garcia MG, Molina JM, Ong E, Shao Y, Piontkowsky D, Das M, McNicholl I, Haubrich R.
    Lancet HIV; 2019 Oct 01; 6(10):e655-e666. PubMed ID: 31578954
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
    Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, Gallant JE, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J, GS-US-236-0102 Study Team.
    J Acquir Immune Defic Syndr; 2013 May 01; 63(1):96-100. PubMed ID: 23392460
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF.
    Mills A, Garner W, Pozniak A, Berenguer J, Speck RM, Bender R, Nguyen T.
    Patient; 2015 Aug 01; 8(4):359-71. PubMed ID: 26045359
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.
    Chauveau M, Billaud E, Bonnet B, Merrien D, Hitoto H, Bouchez S, Michau C, Hall N, Perez L, Sécher S, Raffi F, Allavena C, COREVIH Pays de la Loire Study Group.
    J Antimicrob Chemother; 2019 Apr 01; 74(4):1021-1027. PubMed ID: 30689937
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Post-exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV.
    Gantner P, Allavena C, Duvivier C, Cabie A, Reynes J, Makinson A, Ravaux I, Bregigeon S, Cotte L, Rey D, Dat'AIDS Study Group.
    HIV Med; 2020 Aug 01; 21(7):463-469. PubMed ID: 32558205
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Post-exposure prophylaxis for human immunodeficiency virus after sexual assault in a Midwestern U.S. emergency department.
    Cherabie JN, Gleason E, Munigala S, Fox B, Trolard A, McCammon C, Hilbert S, Casabar E, Reno H, Liang SY.
    Am J Emerg Med; 2021 Nov 01; 49():117-123. PubMed ID: 34102456
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
    Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, Cheng AK, Miller MD, White KL.
    HIV Clin Trials; 2014 Nov 01; 15(5):218-30. PubMed ID: 25350960
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
    Milinkovic A, Benn P, Arenas-Pinto A, Brima N, Copas A, Clarke A, Fisher M, Schembri G, Hawkins D, Williams A, Gilson R, MiPEP Trial Team.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1760-1768. PubMed ID: 28369381
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
    German P, Warren D, West S, Hui J, Kearney BP.
    J Acquir Immune Defic Syndr; 2010 Nov 01; 55(3):323-9. PubMed ID: 20683270
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.